A Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients With Huntington's Disease

Trial Profile

A Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients With Huntington's Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Jul 2017

At a glance

  • Drugs Pridopidine (Primary)
  • Indications Huntington's disease
  • Focus Adverse reactions
  • Acronyms Open PRIDE-HD
  • Sponsors Teva Branded Pharmaceutical Products R&D
  • Most Recent Events

    • 15 Sep 2016 According to a Teva Pharmaceutical Industries media release, company will conduct a substudy towards the end of the year in the US and Canada.
    • 10 May 2016 Time frame for primary endpoint changed from 52 weeks to 104 weeks.
    • 10 May 2016 Planned number of patients changed from 400 to 300.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top